The relationship between serum leptin, insulin-like growth factor-1, and insulin-like growth factor binding protein-3 levels and clinical parameters in primary fibromyalgia patients.
Journal
Revista da Associacao Medica Brasileira (1992)
ISSN: 1806-9282
Titre abrégé: Rev Assoc Med Bras (1992)
Pays: Brazil
ID NLM: 9308586
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
06
2023
accepted:
04
07
2023
medline:
6
10
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
The aim of this study was to investigate the levels of leptin, growth hormone, insulin-like growth factor-1, and insulin-like growth factor binding protein-3 and their relations with clinical parameters in patients with primary fibromyalgia and healthy controls. Our study was performed on 30 female patients with primary fibromyalgia and 30 healthy controls. The levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 were measured by a two-site immunoradiometric assay. The serum level of leptin was measured by the ELISA kit. The serum level of leptin was significantly higher, but the serum levels of insulin-like growth factor-1 were significantly lower in patients with fibromyalgia syndrome than healthy controls (p<0.001). The leptin level was positively correlated with the Visual Analog Scale, Fibromyalgia Impact Questionnaire score, Beck Depression Inventory score, tender point count, age, and duration of disease (p<0.001), but it was negatively correlated with insulin-like growth factor-1 (p<0.001). The insulin-like growth factor-1 level was negatively correlated with age, Visual Analog Scale, Fibromyalgia Impact Questionnaire and Beck Depression Inventory scores, duration of disease, and tender point count (p<0.001). Our results indicate that high levels of serum leptin and low levels of serum insulin-like growth factor-1 may play a role in the physiopathogenesis of fibromyalgia and may be related to some symptoms.
Identifiants
pubmed: 37792867
pii: S0104-42302023001000614
doi: 10.1590/1806-9282.20230240
pmc: PMC10547486
pii:
doi:
Substances chimiques
Insulin-Like Growth Factor I
67763-96-6
Leptin
0
IGFBP3 protein, human
0
IGF1 protein, human
0
LEP protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20230240Références
Int J Environ Res Public Health. 2020 Jun 26;17(12):
pubmed: 32604939
Scand J Pain. 2019 Dec 18;20(1):77-86
pubmed: 31596726
J Rheumatol. 1997 Jul;24(7):1384-9
pubmed: 9228141
Rheumatol Int. 2014 Nov;34(11):1593-8
pubmed: 24671500
Arthritis Res Ther. 2012 Jul 09;14(4):R162
pubmed: 22776095
Clin Rheumatol. 2022 Apr;41(4):1235-1240
pubmed: 35067767
Pain Res Manag. 2012 Mar-Apr;17(2):89-92
pubmed: 22518370
Clinics (Sao Paulo). 2012;67(3):283-7
pubmed: 22473412
JBI Evid Synth. 2020 Nov 2;19(3):695-701
pubmed: 33136710
Acta Neurol Belg. 2020 Jun;120(3):595-599
pubmed: 30547374
Healthcare (Basel). 2023 Jan 11;11(2):
pubmed: 36673591
Int J Environ Res Public Health. 2023 Jan 27;20(3):
pubmed: 36767626
North Clin Istanb. 2018 Apr 16;5(2):102-108
pubmed: 30374474
J Rheumatol. 2003 Apr;30(4):809-14
pubmed: 12672204
Growth Horm IGF Res. 2007 Feb;17(1):82-8
pubmed: 17289417
Korean J Pain. 2019 Apr 01;32(2):120-128
pubmed: 31091511
Joint Bone Spine. 2007 Oct;74(5):477-81
pubmed: 17689128
J Pain Res. 2023 Jan 25;16:205-219
pubmed: 36721849
Arch Endocrinol Metab. 2017 May-Jun;61(3):249-256
pubmed: 28226002